← Back to Home

Sac-TMT extends survival in Phase 3 gastroesophageal adenocarcinoma trial, but progression endpoint not met

A global trial of 473 patients offers a new survival signal for advanced disease after multiple lines of treatment; exactly how much time is gained, and what treatment burdens accompany it, await the full data.

By SURL BioNews

For patients with advanced gastroesophageal adenocarcinoma who have received at least two lines of systemic therapy, whether the next drug can extend life is central to treatment decisions. On November 20, Merck announced that the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) improved overall survival in the global Phase 3 TroFuse-015 trial, meeting the primary endpoint. However, the secondary endpoint of progression-free survival was not met.

The results came from a randomized, open-label trial of 473 patients (NCT06356311) with unresectable locally advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma. The study compared sac-TMT with the physician’s choice of one of four treatments: trifluridine/tipiracil, irinotecan, paclitaxel, or docetaxel. Merck said the survival improvement in the final analysis was statistically significant and clinically meaningful, but has not yet disclosed the hazard ratio or median survival in either group, leaving the magnitude of benefit unclear.

Trial information compiled by CancerNetwork shows that patients in the sac-TMT group received 4 milligrams per kilogram on days 1, 15, and 29 of each six-week cycle. Enrollment did not require a specific level of tumor TROP2 expression, but patients had to have an ECOG performance status of 0 or 1, indicating relatively good ability to carry out daily activities. The results therefore cannot be assumed to apply to patients with poorer performance status.

The differing results for the two survival measures will be a key issue to clarify when the full data are released. Overall survival measures how long patients live, while progression-free survival tracks the time before disease progression or death. The latter, assessed by blinded independent central review, did not meet the trial’s specified target. Although the objective response rate numerically favored sac-TMT, it was not formally tested for statistical significance under the prespecified analysis plan and cannot be regarded as another confirmed efficacy finding.

On safety, Merck said no new safety signals were identified and the overall profile was consistent with previous studies. However, the announcement did not provide detailed adverse event or treatment discontinuation data, and “no new signals” is insufficient to establish the extent of the treatment burden. The company also said survival results were generally consistent across subgroups with different levels of TROP2 expression. Until subgroup sample sizes and effect estimates are disclosed, this should not be taken to mean that all patients benefit equally.

Background

Sac-TMT uses an antibody to recognize TROP2 and carries a topoisomerase I inhibitor, with the aim of delivering a cytotoxic drug to tumors. It was developed by Kelun-Biotech, and Merck acquired development and commercialization rights outside Greater China. Compared with the approach of exploring an ADC combined with Keytruda as first-line treatment for lung cancer, TroFuse-015 addresses a different question: whether this ADC alone can extend survival in gastroesophageal adenocarcinoma after multiple lines of treatment.

Merck plans to present the data at a future medical meeting and share them with regulatory authorities. The current results support moving this treatment approach forward, but do not yet amount to approval for this indication. Median survival, survival curves, and complete safety data will determine how much practical difference this statistical success can make for patients.

References

  1. Merck
  2. CancerNetwork